EUVIMEDEUVIMED entdecken
Crossref

FoxO1 as the critical target of puerarin to inhibit osteoclastogenesis and bone resorption

Yanling Feng iD, Xulei Tang

Journal of Pharmacy and Pharmacology · 2024

DOI: 10.1093/jpp/rgae033 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2024. Verfasst von Yanling Feng und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, The Second Hospital of Lanzhou University, Lanzhou 730030, China. Hauptthemen laut MEDLINE: Isoflavones, Forkhead Box Protein O1, Osteogenesis, Osteoclasts. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Lanzhou University Second Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Elevated reactive oxygen species levels promote excessive osteoclastogenesis and bone resorption. Puerarin, a natural antioxidant, can prevent bone loss through its antioxidant effects; however, the underlying molecular mechanism remains unclear. This study aimed to explore the effects of puerarin on osteoclast differentiation and bone resorption by regulating the PI3K/AKT/FoxO1 signaling pathway. Materials and methods An ovariectomized (OVX) rat model of osteoporosis and H2O2-induced oxidative cell model of RAW 264.7 cells were established. The following indices were measured including bone μ-CT scanning and the protein expression levels of FoxO1, p-FoxO1, and catalase were detected using western blotting.

Results

Puerarin strongly alleviated oxidative stress-induced bone loss in OVX rats in vivo owing to its antioxidant effects. Puerarin improved the oxidative stress status of cells and inhibited osteoclast formation in vitro. Moreover, the protein expression of FoxO1 and its downstream target, catalase, was upregulated by puerarin.

Conclusions

Puerarin improved the OPG/RANKL ratio, upregulated the protein expression and transcriptional activity of FoxO1, and suppressed the differentiation of RAW264.7 cells into osteoclasts. FoxO1 is a pivotal target of puerarin to confer anti-osteoporosis effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IsoflavonesForkhead Box Protein O1OsteogenesisOsteoclastsBone ResorptionOxidative StressSignal TransductionOsteoporosisOvariectomyCell DifferentiationAnimalsMiceRAW 264.7 CellsFemaleRatsAntioxidantsRats, Sprague-DawleyRANK LigandDisease Models, AnimalProto-Oncogene Proteins c-aktCatalasePhosphatidylinositol 3-Kinases

Stichwörter der Autor:innen

FoxO1osteoclastsosteoporosisoxidative stresspuerarin

Substanzen

IsoflavonespuerarinForkhead Box Protein O1AntioxidantsFoxo1 protein, mouseRANK LigandProto-Oncogene Proteins c-aktCatalasePhosphatidylinositol 3-Kinases

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, The Second Hospital of Lanzhou University, Lanzhou 730030, China.
  • Department of Endocrinology, The First Hospital of Lanzhou University, Lanzhou 730000, China.

ORCID-Profile: Yanling Feng

Förderung

  • Lanzhou University Second Hospital

Zitieren

APA

Feng, Y., & Tang, X. (2024). FoxO1 as the critical target of puerarin to inhibit osteoclastogenesis and bone resorption. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgae033

Vancouver

Feng Y, Tang X. FoxO1 as the critical target of puerarin to inhibit osteoclastogenesis and bone resorption. Journal of Pharmacy and Pharmacology. 2024. doi:10.1093/jpp/rgae033

BibTeX
@article{Feng2024,
  author = {Feng, Yanling and Tang, Xulei},
  title = {FoxO1 as the critical target of puerarin to inhibit osteoclastogenesis and bone resorption},
  journal = {Journal of Pharmacy and Pharmacology},
  year = {2024},
  doi = {10.1093/jpp/rgae033}
}
Kostenlos starten →